{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:49:02Z","timestamp":1768805342044,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014116","name":"Ontario Veterinary College, University of Guelph","doi-asserted-by":"publisher","award":["Pet Trust Scholar's Program"],"award-info":[{"award-number":["Pet Trust Scholar's Program"]}],"id":[{"id":"10.13039\/100014116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014116","name":"Ontario Veterinary College, University of Guelph","doi-asserted-by":"publisher","award":["Graduate Scholarship"],"award-info":[{"award-number":["Graduate Scholarship"]}],"id":[{"id":"10.13039\/100014116","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pet Trust Foundation","award":["Art Rouse Cancer Biology Graduate Stipend"],"award-info":[{"award-number":["Art Rouse Cancer Biology Graduate Stipend"]}]},{"DOI":"10.13039\/501100000023","name":"Government of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008986","name":"University of Guelph","doi-asserted-by":"publisher","award":["Brock Doctoral Scholarship"],"award-info":[{"award-number":["Brock Doctoral Scholarship"]}],"id":[{"id":"10.13039\/100008986","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013873","name":"Government of Ontario","doi-asserted-by":"publisher","award":["Ontario Graduate Scholarship"],"award-info":[{"award-number":["Ontario Graduate Scholarship"]}],"id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000094","name":"Ontario Ministry of Agriculture, Food and Rural Affairs","doi-asserted-by":"publisher","award":["Highly Qualified Personnel Scholarship"],"award-info":[{"award-number":["Highly Qualified Personnel Scholarship"]}],"id":[{"id":"10.13039\/501100000094","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Centre of Excellence in Biotherapeutics for Cancer Treatment"},{"name":"The Smiling Blue Skies Cancer Fund","award":["Project #800013"],"award-info":[{"award-number":["Project #800013"]}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["Discovery Grant #436264"],"award-info":[{"award-number":["Discovery Grant #436264"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vaccination can prevent viral infections via virus-specific T cells, among other mechanisms. A goal of oncolytic virotherapy is replication of oncolytic viruses (OVs) in tumors, so pre-existing T cell immunity against an OV-encoded transgene would seem counterproductive. We developed a treatment for melanomas by pre-vaccinating against an oncolytic vesicular stomatitis virus (VSV)-encoded tumor antigen. Surprisingly, when the VSV-vectored booster vaccine was administered at the peak of the primary effector T cell response, oncolysis was not abrogated. We sought to determine how oncolysis was retained during a robust T cell response against the VSV-encoded transgene product. A murine melanoma model was used to identify two mechanisms that enable this phenomenon. First, tumor-infiltrating T cells had reduced cytopathic potential due to immunosuppression. Second, virus-induced lymphopenia acutely removed virus-specific T cells from tumors. These mechanisms provide a window of opportunity for replication of oncolytic VSV and rationale for a paradigm change in oncolytic virotherapy, whereby immune responses could be intentionally induced against a VSV-encoded melanoma-associated antigen to improve safety without abrogating oncolysis.<\/jats:p>","DOI":"10.1038\/s41598-021-94483-z","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T10:02:50Z","timestamp":1627380170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis"],"prefix":"10.1038","volume":"11","author":[{"given":"Amanda W. K.","family":"AuYeung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Mould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley A.","family":"Stegelmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob P.","family":"van Vloten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalil","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Paul","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byram W.","family":"Bridle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"94483_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fonc.2017.00195","volume":"7","author":"A Howells","year":"2017","unstructured":"Howells, A., Marelli, G., Lemoine, N. R. & Wang, Y. Oncolytic viruses\u2014Interaction of virus and tumor cells in the battle to eliminate cancer. Front. Oncol. 7, 195. https:\/\/doi.org\/10.3389\/fonc.2017.00195 (2017).","journal-title":"Front. Oncol."},{"key":"94483_CR2","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/mt.2010.98","volume":"18","author":"BW Bridle","year":"2010","unstructured":"Bridle, B. W. et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther. 18, 1430\u20131439. https:\/\/doi.org\/10.1038\/mt.2010.98 (2010).","journal-title":"Mol. Ther."},{"key":"94483_CR3","doi-asserted-by":"publisher","unstructured":"Bridle, B. W. et al. Privileged antigen presentation in splenic B cell follicles maximizes T cell responses in prime-boost vaccination. J. Immunol. (Baltimore, Md. : 1950) 196, 4587\u20134595. https:\/\/doi.org\/10.4049\/jimmunol.1600106 (2016).","DOI":"10.4049\/jimmunol.1600106"},{"key":"94483_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/mt.2013.249","volume":"22","author":"JG Pol","year":"2014","unstructured":"Pol, J. G. et al. Maraba virus as a potent oncolytic vaccine vector. Mol. Ther. 22, 420\u2013429. https:\/\/doi.org\/10.1038\/mt.2013.249 (2014).","journal-title":"Mol. Ther."},{"key":"94483_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/2326-6066.Cir-17-0102","volume":"5","author":"MJ Atherton","year":"2017","unstructured":"Atherton, M. J. et al. Customized viral immunotherapy for HPV-associated cancer. Cancer Immunol. Res. 5, 847\u2013859. https:\/\/doi.org\/10.1158\/2326-6066.Cir-17-0102 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"94483_CR6","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.vaccine.2018.02.070","volume":"36","author":"MJ Atherton","year":"2018","unstructured":"Atherton, M. J. et al. Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. Vaccine 36, 2181\u20132192. https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.070 (2018).","journal-title":"Vaccine"},{"key":"94483_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1445459","volume":"7","author":"MJ Atherton","year":"2018","unstructured":"Atherton, M. J. et al. Transforming the prostatic tumor microenvironment with oncolytic virotherapy. Oncoimmunology 7, e1445459. https:\/\/doi.org\/10.1080\/2162402x.2018.1445459 (2018).","journal-title":"Oncoimmunology"},{"key":"94483_CR8","doi-asserted-by":"publisher","unstructured":"Younan, P. et al. Ebola virus binding to Tim-1 on T lymphocytes induces a cytokine storm. mBio 8. https:\/\/doi.org\/10.1128\/mBio.00845-17 (2017).","DOI":"10.1128\/mBio.00845-17"},{"key":"94483_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.virusres.2013.06.003","volume":"176","author":"E Hastie","year":"2013","unstructured":"Hastie, E., Cataldi, M., Marriott, I. & Grdzelishvili, V. Z. Understanding and altering cell tropism of vesicular stomatitis virus. Virus Res. 176, 16\u201332. https:\/\/doi.org\/10.1016\/j.virusres.2013.06.003 (2013).","journal-title":"Virus Res."},{"key":"94483_CR10","doi-asserted-by":"publisher","unstructured":"Lanitis, E., Dangaj, D., Irving, M. & Coukos, G. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann. Oncol. 28, xii18\u2013xii32. https:\/\/doi.org\/10.1093\/annonc\/mdx238 (2017).","DOI":"10.1093\/annonc\/mdx238"},{"key":"94483_CR11","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.150661","volume":"3","author":"SR Stipp","year":"2016","unstructured":"Stipp, S. R., Iniguez, A., Wan, F. & Wodarz, D. Timing of CD8 T cell effector responses in viral infections. R. Soc. Open Sci. 3, 150661. https:\/\/doi.org\/10.1098\/rsos.150661 (2016).","journal-title":"R. Soc. Open Sci."},{"key":"94483_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1016700","volume":"4","author":"AA Wu","year":"2015","unstructured":"Wu, A. A., Drake, V., Huang, H. S., Chiu, S. & Zheng, L. Reprogramming the tumor microenvironment: Tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 4, e1016700. https:\/\/doi.org\/10.1080\/2162402x.2015.1016700 (2015).","journal-title":"Oncoimmunology"},{"key":"94483_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: A case for synergistic therapies. Cancer Cell 31, 311\u2013325. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.008 (2017).","journal-title":"Cancer Cell"},{"key":"94483_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0008-8749(83)90046-1","volume":"79","author":"A Schattner","year":"1983","unstructured":"Schattner, A., Meshorer, A. & Wallach, D. Involvement of interferon in virus-induced lymphopenia. Cell. Immunol. 79, 11\u201325 (1983).","journal-title":"Cell. Immunol."},{"key":"94483_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/humc.2016.061","volume":"27","author":"L Zhang","year":"2016","unstructured":"Zhang, L. et al. Safety studies in tumor and non-tumor-bearing mice in support of clinical trials using oncolytic VSV-IFNbeta-NIS. Hum. Gene. Ther. Clin. Dev. 27, 111\u2013122. https:\/\/doi.org\/10.1089\/humc.2016.061 (2016).","journal-title":"Hum. Gene. Ther. Clin. Dev."},{"key":"94483_CR16","first-page":"905","volume":"145","author":"H Okada","year":"2000","unstructured":"Okada, H. et al. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients. Adv. Virol. 145, 905\u2013920 (2000).","journal-title":"Adv. Virol."},{"key":"94483_CR17","doi-asserted-by":"publisher","unstructured":"Boonnak, K. et al. Lymphopenia associated with highly virulent H5N1 virus infection due to plasmacytoid dendritic cell mediated apoptosis of T cells. J. Immunol. (Baltimore, Md. : 1950) 192, 5906\u20135912. https:\/\/doi.org\/10.4049\/jimmunol.1302992 (2014).","DOI":"10.4049\/jimmunol.1302992"},{"key":"94483_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2362.1991.tb01378.x","volume":"21","author":"AH Span","year":"1991","unstructured":"Span, A. H. et al. The effect of virus infection on the adherence of leukocytes or platelets to endothelial cells. Eur. J. Clin. Invest. 21, 331\u2013338 (1991).","journal-title":"Eur. J. Clin. Invest."},{"key":"94483_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0022-510X(94)90299-2","volume":"122","author":"K Ichinose","year":"1994","unstructured":"Ichinose, K. et al. Characterization of adherent T cells to human endothelial cells in patients with HTLV-I-associated myelopathy. J. Neurol. Sci. 122, 204\u2013209. https:\/\/doi.org\/10.1016\/0022-510X(94)90299-2 (1994).","journal-title":"J. Neurol. Sci."},{"key":"94483_CR20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1182\/blood.V76.5.965.965","volume":"76","author":"TM Carlos","year":"1990","unstructured":"Carlos, T. M. et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 76, 965\u2013970 (1990).","journal-title":"Blood"},{"key":"94483_CR21","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/mt.2012.265","volume":"21","author":"BW Bridle","year":"2013","unstructured":"Bridle, B. W. et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol. Ther. J. Am. Soc. Gene Ther. 21, 887\u2013894. https:\/\/doi.org\/10.1038\/mt.2012.265 (2013).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"94483_CR22","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26013","volume":"2","author":"BW Bridle","year":"2013","unstructured":"Bridle, B. W. et al. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. Oncoimmunology 2, e26013. https:\/\/doi.org\/10.4161\/onci.26013 (2013).","journal-title":"Oncoimmunology"},{"key":"94483_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1128\/cmr.00090-16","volume":"30","author":"CD Russell","year":"2017","unstructured":"Russell, C. D., Unger, S. A., Walton, M. & Schwarze, J. The human immune response to respiratory syncytial virus infection. Clin. Microbiol. Rev. 30, 481\u2013502. https:\/\/doi.org\/10.1128\/cmr.00090-16 (2017).","journal-title":"Clin. Microbiol. Rev."},{"key":"94483_CR24","doi-asserted-by":"crossref","unstructured":"Patel, M. R. & Kratzke, R. A. in Translating Gene Therapy to the Clinic (eds. Laurence, J. & Franklin, M.) 261\u2013279 (Academic Press, 2015).","DOI":"10.1016\/B978-0-12-800563-7.00017-8"},{"key":"94483_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1074-7613(00)80169-7","volume":"12","author":"ES Jos\u00e9","year":"2000","unstructured":"Jos\u00e9, E. S., Borroto, A., Niedergang, F., Alcover, A. & Alarc\u00f3n, B. Triggering the TCR complex causes the downregulation of nonengaged receptors by a signal transduction-dependent mechanism. Immunity 12, 161\u2013170. https:\/\/doi.org\/10.1016\/S1074-7613(00)80169-7 (2000).","journal-title":"Immunity"},{"key":"94483_CR26","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1084\/jem.185.10.1859","volume":"185","author":"S Valitutti","year":"1997","unstructured":"Valitutti, S., M\u00fcller, S., Salio, M. & Lanzavecchia, A. Degradation of T cell receptor (TCR)\u2013CD3-\u03b6 complexes after antigenic stimulation. J. Exp. Med. 185, 1859\u20131864 (1997).","journal-title":"J. Exp. Med."},{"key":"94483_CR27","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1084\/jem.20062376","volume":"204","author":"Z Xiao","year":"2007","unstructured":"Xiao, Z., Mescher, M. F. & Jameson, S. C. Detuning CD8 T cells: Down-regulation of CD8 expression, tetramer binding, and response during CTL activation. J. Exp. Med. 204, 2667\u20132677. https:\/\/doi.org\/10.1084\/jem.20062376 (2007).","journal-title":"J. Exp. Med."},{"key":"94483_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12307-013-0143-1","volume":"7","author":"AA Hurwitz","year":"2014","unstructured":"Hurwitz, A. A., Cuss, S. M., Stagliano, K. E. & Zhu, Z. T cell avidity and tumor immunity: Problems and solutions. Cancer Microenviron. 7, 1\u20139. https:\/\/doi.org\/10.1007\/s12307-013-0143-1 (2014).","journal-title":"Cancer Microenviron."},{"key":"94483_CR29","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.4049\/jimmunol.180.5.3122","volume":"180","author":"SB Wong","year":"2008","unstructured":"Wong, S. B., Bos, R. & Sherman, L. A. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J. Immunol. 180, 3122\u20133131 (2008).","journal-title":"J. Immunol."},{"key":"94483_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1158\/2326-6066.Cir-13-0145","volume":"2","author":"CM Black","year":"2014","unstructured":"Black, C. M., Armstrong, T. D. & Jaffee, E. M. Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2\/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol. Res. 2, 307\u2013319. https:\/\/doi.org\/10.1158\/2326-6066.Cir-13-0145 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"94483_CR31","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.4049\/jimmunol.169.10.5522","volume":"169","author":"U Blohm","year":"2002","unstructured":"Blohm, U. et al. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J. Immunol. 169, 5522\u20135530 (2002).","journal-title":"J. Immunol."},{"key":"94483_CR32","doi-asserted-by":"publisher","unstructured":"Petit, A.-E. et al. A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion. Nat. Commun. 7, 12242. https:\/\/doi.org\/10.1038\/ncomms12242. https:\/\/www.nature.com\/articles\/ncomms12242#supplementary-information (2016).","DOI":"10.1038\/ncomms12242"},{"key":"94483_CR33","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature19364","volume":"537","author":"R Eil","year":"2016","unstructured":"Eil, R. et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537, 539\u2013543. https:\/\/doi.org\/10.1038\/nature19364 (2016).","journal-title":"Nature"},{"key":"94483_CR34","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.4049\/jimmunol.172.9.5553","volume":"172","author":"NL La Gruta","year":"2004","unstructured":"La Gruta, N. L., Turner, S. J. & Doherty, P. C. Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: Correlation of cytokine profile and TCR avidity. J. Immunol. 172, 5553\u20135560 (2004).","journal-title":"J. Immunol."},{"key":"94483_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2337\/db12-0315","volume":"62","author":"RR Knight","year":"2013","unstructured":"Knight, R. R. et al. Human beta-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity. Diabetes 62, 205\u2013213. https:\/\/doi.org\/10.2337\/db12-0315 (2013).","journal-title":"Diabetes"},{"key":"94483_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nri3596","volume":"14","author":"K Minton","year":"2013","unstructured":"Minton, K. Mechanisms of T cell polyfunctionality. Nat. Rev. Immunol. 14, 7. https:\/\/doi.org\/10.1038\/nri3596 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"94483_CR37","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1182\/blood-2009-02-206557","volume":"113","author":"JR Almeida","year":"2009","unstructured":"Almeida, J. R. et al. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 113, 6351\u20136360. https:\/\/doi.org\/10.1182\/blood-2009-02-206557 (2009).","journal-title":"Blood"},{"key":"94483_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1164\/rccm.201504-0733OC","volume":"193","author":"LD Snyder","year":"2016","unstructured":"Snyder, L. D. et al. Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation. Am. J. Respir. Crit. Care Med. 193, 78\u201385. https:\/\/doi.org\/10.1164\/rccm.201504-0733OC (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"94483_CR39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0091-679X(04)75020-7","volume":"75","author":"MR Betts","year":"2004","unstructured":"Betts, M. R. & Koup, R. A. Detection of T-cell degranulation: CD107a and b. Methods Cell Biol. 75, 497\u2013512 (2004).","journal-title":"Methods Cell Biol."},{"key":"94483_CR40","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1038\/mt.2009.154","volume":"17","author":"BW Bridle","year":"2009","unstructured":"Bridle, B. W. et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol. Ther. J. Am. Soc. Gene Ther. 17, 1814\u20131821. https:\/\/doi.org\/10.1038\/mt.2009.154 (2009).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"94483_CR41","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1158\/0008-5472.Can-06-3974","volume":"67","author":"RM Diaz","year":"2007","unstructured":"Diaz, R. M. et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Can. Res. 67, 2840\u20132848. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-3974 (2007).","journal-title":"Can. Res."},{"key":"94483_CR42","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1158\/0008-5472.Can-12-0600","volume":"72","author":"DM Rommelfanger","year":"2012","unstructured":"Rommelfanger, D. M. et al. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Can. Res. 72, 4753\u20134764. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-0600 (2012).","journal-title":"Can. Res."},{"key":"94483_CR43","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.ymthe.2020.08.013","volume":"28","author":"AL Huff","year":"2020","unstructured":"Huff, A. L. et al. Vesicular stomatitis virus encoding a destabilized tumor antigen improves activation of anti-tumor T cell responses. Mol. Ther. J. Am. Soc. Gene Ther. 28, 2540\u20132552. https:\/\/doi.org\/10.1016\/j.ymthe.2020.08.013 (2020).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"94483_CR44","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1128\/JVI.02749-15","volume":"90","author":"C Xia","year":"2016","unstructured":"Xia, C. et al. Hemagglutinin of influenza A virus antagonizes type I interferon (IFN) responses by inducing degradation of type I IFN receptor 1. J. Virol. 90, 2403\u20132417. https:\/\/doi.org\/10.1128\/JVI.02749-15 (2016).","journal-title":"J. Virol."},{"key":"94483_CR45","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1182\/blood-2006-06-027599","volume":"108","author":"E Kamphuis","year":"2006","unstructured":"Kamphuis, E., Junt, T., Waibler, Z., Forster, R. & Kalinke, U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108, 3253\u20133261. https:\/\/doi.org\/10.1182\/blood-2006-06-027599 (2006).","journal-title":"Blood"},{"key":"94483_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/jlb.45.2.155","volume":"45","author":"TR Ulich","year":"1989","unstructured":"Ulich, T. R., del Castillo, J., Ni, R. X., Bikhazi, N. & Calvin, L. Mechanisms of tumor necrosis factor alpha-induced lymphopenia, neutropenia, and biphasic neutrophilia: A study of lymphocyte recirculation and hematologic interactions of TNF alpha with endogenous mediators of leukocyte trafficking. J. Leukoc. Biol. 45, 155\u2013167 (1989).","journal-title":"J. Leukoc. Biol."},{"key":"94483_CR47","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/j.1582-4934.2009.00811.x","volume":"13","author":"HF Langer","year":"2009","unstructured":"Langer, H. F. & Chavakis, T. Leukocyte \u2013 Endothelial interactions in inflammation. J. Cell Mol. Med. 13, 1211\u20131220. https:\/\/doi.org\/10.1111\/j.1582-4934.2009.00811.x (2009).","journal-title":"J. Cell Mol. Med."},{"key":"94483_CR48","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1158\/0008-5472.Can-14-2458","volume":"74","author":"CY Slaney","year":"2014","unstructured":"Slaney, C. Y., Kershaw, M. H. & Darcy, P. K. Trafficking of T cells into tumors. Can. Res. 74, 7168\u20137174. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-2458 (2014).","journal-title":"Can. Res."},{"key":"94483_CR49","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1016\/j.vaccine.2015.08.096","volume":"33","author":"AB Frey","year":"2015","unstructured":"Frey, A. B. Suppression of T cell responses in the tumor microenvironment. Vaccine 33, 7393\u20137400. https:\/\/doi.org\/10.1016\/j.vaccine.2015.08.096 (2015).","journal-title":"Vaccine"},{"key":"94483_CR50","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/mt.2013.255","volume":"22","author":"AJ McGray","year":"2014","unstructured":"McGray, A. J. et al. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol. Ther. J. Am. Soc. Gene Ther. 22, 206\u2013218. https:\/\/doi.org\/10.1038\/mt.2013.255 (2014).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"94483_CR51","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/bies.201400070","volume":"36","author":"CH Lineweaver","year":"2014","unstructured":"Lineweaver, C. H., Davies, P. C. & Vincent, M. D. Targeting cancer\u2019s weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model. BioEssays News Rev. Mol. Cell. Dev. Biol. 36, 827\u2013835. https:\/\/doi.org\/10.1002\/bies.201400070 (2014).","journal-title":"BioEssays News Rev. Mol. Cell. Dev. Biol."},{"key":"94483_CR52","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/bmj.332.7534.170","volume":"332","author":"Y Chernajovsky","year":"2006","unstructured":"Chernajovsky, Y., Layward, L. & Lemoine, N. Fighting cancer with oncolytic viruses. BMJ Br. Med. J. 332, 170\u2013172 (2006).","journal-title":"BMJ Br. Med. J."},{"key":"94483_CR53","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2217\/fmb.09.28","volume":"4","author":"R Alemany","year":"2009","unstructured":"Alemany, R. & Cascallo, M. Oncolytic viruses from the perspective of the immune system. Future Microbiol. 4, 527\u2013536. https:\/\/doi.org\/10.2217\/fmb.09.28 (2009).","journal-title":"Future Microbiol."},{"key":"94483_CR54","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.3390\/v7122938","volume":"7","author":"S Turnbull","year":"2015","unstructured":"Turnbull, S. et al. Evidence for oncolytic virotherapy: Where have we got to and where are we going?. Viruses 7, 6291\u20136312. https:\/\/doi.org\/10.3390\/v7122938 (2015).","journal-title":"Viruses"},{"key":"94483_CR55","doi-asserted-by":"publisher","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 18, e3000410. https:\/\/doi.org\/10.1371\/journal.pbio.3000410 (2020).","DOI":"10.1371\/journal.pbio.3000410"},{"key":"94483_CR56","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1089\/10430340050015590","volume":"11","author":"P Ng","year":"2000","unstructured":"Ng, P., Parks, R. J., Cummings, D. T., Evelegh, C. M. & Graham, F. L. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum. Gene Ther. 11, 693\u2013699. https:\/\/doi.org\/10.1089\/10430340050015590 (2000).","journal-title":"Hum. Gene Ther."},{"key":"94483_CR57","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/sj.gt.3302232","volume":"11","author":"T McKelvey","year":"2004","unstructured":"McKelvey, T., Tang, A., Bett, A. J., Casimiro, D. R. & Chastain, M. T-cell response to adenovirus hexon and DNA-binding protein in mice. Gene Ther. 11, 791\u2013796. https:\/\/doi.org\/10.1038\/sj.gt.3302232 (2004).","journal-title":"Gene Ther."},{"key":"94483_CR58","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.omtm.2019.01.012","volume":"13","author":"JP van Vloten","year":"2019","unstructured":"van Vloten, J. P. et al. Quantifying antigen-specific T cell responses when using antigen-agnostic immunotherapies. Mol. Ther. Methods Clin. Dev. 13, 154\u2013166. https:\/\/doi.org\/10.1016\/j.omtm.2019.01.012 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"94483_CR59","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0022-1759(01)00359-3","volume":"253","author":"H Lecoeur","year":"2001","unstructured":"Lecoeur, H., Fevrier, M., Garcia, S., Riviere, Y. & Gougeon, M. L. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J. Immunol. Methods 253, 177\u2013187. https:\/\/doi.org\/10.1016\/s0022-1759(01)00359-3 (2001).","journal-title":"J. Immunol. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94483-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94483-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94483-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:40:30Z","timestamp":1670067630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94483-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94483"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94483-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15290"}}